In the near future oral polio vaccine (OPV) will be replaced by inactivated polio vaccine (IPV) as part of the eradication program of polio. For that reason, there is a need for substantial amount of safe and more affordable IPV for low-income countries. Bioneedles, which are biodegradable mini-implants, have the potential to deliver vaccines outside the cold-chain and administer them without the use of needles and syringes. In the current study, Bioneedles were filled with IPV, subsequently lyophilized, and antigenic recoveries were determined both directly after IPV-Bioneedle preparation as well as after elevated stability testing. Further, we assessed the immunogenicity of IPV-Bioneedles in rats and the residence time at the site of administration. Trivalent IPV was formulated in Bioneedles with recoveries of 101 10%, 113 18%, and 92 15%, respectively for serotypes 1, 2 and 3. IPV in Bioneedles is more resistant to elevated temperatures than liquid IPV: liquid IPV retained less than half of its antigenicity after 1 day at 45 degrees C and IPV in Bioneedles showed remaining recoveries of 80 10%, 85 4% and 63 4% for the three serotypes. In vivo imaging revealed that IPV administered via Bioneedles as well as subcutaneously injected liquid IPV showed a retention time of 3 days at the site of administration. Finally, an immunogenicity study showed that IPV-filled Bioneedles are able to induce virus-neutralizing antibody titers similar to those obtained by liquid intramuscular injection when administered in a booster regime. The addition of LPS-derivate PagL in IPV-filled Bioneedles did not increase immunogenicity compared to IPV-Bioneedles without adjuvant. The current study demonstrates the pre-clinical proof of concept of IPV-filled Bioneedles as a syringe-free alternative delivery system. Further pre-clinical and clinical studies will be required to assess the feasibility whether IPV-Bioneedles show sufficient safety and efficacy, and may contribute to the efforts to eradicate and prevent polio in the future. (C) 2015 The Authors. Published by Elsevier Ltd.
机构:
PATH, Seattle, WA 98121 USAPATH, Seattle, WA 98121 USA
White, Jessica A.
Blum, Jeremy S.
论文数: 0引用数: 0
h-index: 0
机构:
PATH, Seattle, WA 98121 USAPATH, Seattle, WA 98121 USA
Blum, Jeremy S.
Hosken, Nancy A.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Washington, Dept Med, Seattle, WA USAPATH, Seattle, WA 98121 USA
Hosken, Nancy A.
Marshak, Joshua O.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Washington, Dept Med, Seattle, WA USAPATH, Seattle, WA 98121 USA
Marshak, Joshua O.
Duncan, Lauren
论文数: 0引用数: 0
h-index: 0
机构:
PATH, Seattle, WA 98121 USAPATH, Seattle, WA 98121 USA
Duncan, Lauren
Zhu, Changcheng
论文数: 0引用数: 0
h-index: 0
机构:
PATH, Seattle, WA 98121 USAPATH, Seattle, WA 98121 USA
Zhu, Changcheng
Norton, Elizabeth B.
论文数: 0引用数: 0
h-index: 0
机构:
Tulane Univ, Sch Med, Dept Microbiol & Immunol, New Orleans, LA 70112 USAPATH, Seattle, WA 98121 USA
Norton, Elizabeth B.
Clements, John D.
论文数: 0引用数: 0
h-index: 0
机构:
Tulane Univ, Sch Med, Dept Microbiol & Immunol, New Orleans, LA 70112 USAPATH, Seattle, WA 98121 USA
Clements, John D.
Koelle, David M.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Washington, Dept Med, Seattle, WA USA
Univ Washington, Dept Lab Med, Seattle, WA 98195 USA
Fred Hutchinson Canc Res Inst, Vaccine & Infect Dis Div, Seattle, WA USA
Univ Washington, Dept Global Hlth, Seattle, WA 98195 USAPATH, Seattle, WA 98121 USA
Koelle, David M.
Chen, Dexiang
论文数: 0引用数: 0
h-index: 0
机构:
PATH, Seattle, WA 98121 USAPATH, Seattle, WA 98121 USA
Chen, Dexiang
Weldon, William C.
论文数: 0引用数: 0
h-index: 0
机构:
Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USAPATH, Seattle, WA 98121 USA
Weldon, William C.
Oberste, M. Steven
论文数: 0引用数: 0
h-index: 0
机构:
Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USAPATH, Seattle, WA 98121 USA
Oberste, M. Steven
Lal, Manjari
论文数: 0引用数: 0
h-index: 0
机构:
PATH, Seattle, WA 98121 USAPATH, Seattle, WA 98121 USA